Here’s what you should know:
1. NIH recommends the treatment to people who have not responded to or who cannot receive similar treatments.
2. Truberzi slows down food movement in the gut.
3. In its phase III trial, Truberzi significantly reduced abdominal pain and diarrhea in IBS-D patients. The drug’s effects are evident in a week and last for six months.
4. United Kingdom-based University Hospitals of North Midlands gastroenterologist Adam Farmer, MD, said to Pharma Times, “Until now doctors have had limited options when it comes to treating IBS-D and unfortunately this has been to the detriment of patients, many of whom endure debilitating symptoms on a daily basis. For doctors to now be able to prescribe Truberzi, a targeted treatment, this will signify real change for IBS-D sufferers.”
More articles on gastroenterology:
GI center to know: Chicago Endoscopy Center
AzurRx BioPharma’s clinical trial hits midway point & more — 3 GI company key notes
Dr. Nitin Kumar speaking to community — 3 key notes
